A new study published in the New England Journal of Medicine reveals that the oral anticoagulant rivaroxaban improves survival rates after a myocardial infarction when given in combination standard antiplatelet therapy
More than 15,500 patients took part in the ATLAS-ACS 2-TIMI 51 trial and were given either a placebo or 2.5 mg or 5 mg of rivaroxaban for over a period of 13 months.
The number of cardiovascular deaths, MI, or strokes was lower in the group taking rivaroxaban at 8.9 percent compared to 10.7 percent in the placebo group.
Lead researcher Michael Gibson of Harvard, who presented the findings at the American Heart Association meeting, said that a number of deaths can be prevented if antiplatelet therapy is used to treat the patients. "One death would be prevented if 56 patients on antiplatelet therapies were treated for two years with rivaroxaban 2.5 mg twice daily", he said.